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ORIGINAL ARTICLE

Circulating and intraprostatic sex steroid hormonal profiles in
relation to male pattern baldness and chest hair density
among men diagnosed with localized prostate cancers
Cindy Ke Zhou1

|

Frank Z. Stanczyk2 | Muhannad Hafi3 |

Carmela C. Veneroso3 | Barlow Lynch4 | Roni T. Falk1 | Shelley Niwa5 |
Eric Emanuel4 | Yu-Tang Gao6 | George P. Hemstreet7 | Ladan Zolfghari3 |
Peter R. Carroll8 | Michael J. Manyak9,10 | Isabell A. Sesterhenn11 |
Paul H. Levine12 | Ann W. Hsing13 | Michael B. Cook1
1 Division

of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

2 Reproductive
3 Department
4 Doctors

Rockville, Maryland

6 Department

of Epidemiology, Shanghai Cancer Institute/Shanghai Jiao Tong University, Shanghai, China

Veterans Administration Medical Center, Omaha, Nebraska

8 Department
9 George

of Epidemiology and Biostatistics, George Washington University, Washington, District of Columbia

Community Hospital, Goddard, Maryland

5 Westat®,

7 Omaha

Endocrine Research Laboratory, Keck School of Medicine, University of Southern California, Los Angeles, California

of Urology, University of California, San Francisco, California

Washington University, Washington, District of Columbia

10 GlaxoSmithKline,
11 Genitourinary
12 Department

London, UK

Pathology, Joint Pathology Center, Silver Spring, Maryland

of Epidemiology, University of Nebraska Omaha, Omaha, Nebraska

13 Department of Medicine and Department of Health Research and Policy, Stanford Prevention Research Center/Cancer Institute, Stanford University,
Stanford, California

Correspondence
Cindy Ke Zhou, PhD, Metabolic Epidemiology
Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute. 9609
Medical Center Drive Rm 6E330, Bethesda MD
20892-9774, USA.
Email: ke.zhou@nih.gov
Funding information
Intramural Program of the Division of Cancer
Epidemiology and Genetics, National Cancer
Institute

Background: Prospective cohort studies of circulating sex steroid hormones and
prostate cancer risk have not provided a consistent association, despite evidence
from animal and clinical studies. However, studies using male pattern baldness as a
proxy of early-life or cumulative androgen exposure have reported significant
associations with aggressive and fatal prostate cancer risk. Given that androgens
underlie the development of patterned hair loss and chest hair, we assessed whether
these two dermatological characteristics were associated with circulating and
intraprostatic concentrations of sex steroid hormones among men diagnosed with
localized prostate cancer.
Methods: We included 248 prostate cancer patients from the NCI Prostate Tissue
Study, who answered surveys and provided a pre-treatment blood sample as well as
fresh frozen adjacent normal prostate tissue. Male pattern baldness and chest hair
density were assessed by trained nurses before surgery. General linear models
estimated geometric means and 95% confidence intervals (95%CIs) of each hormone
variable by dermatological phenotype with adjustment for potential confounding
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variables. Subgroup analyses were performed by Gleason score (<7 vs ≥7) and race
(European American vs. African American).
Results: We found strong positive associations of balding status with serum
testosterone, dihydrotestosterone (DHT), estradiol, and sex hormone-binding
globulin (SHBG), and a weak association with elevated intraprostatic testosterone.
Conversely, neither circulating nor intraprostatic sex hormones were statistically
significantly associated with chest hair density. Age-adjusted correlation between
binary balding status and three-level chest hair density was weak (r = 0.05). There was
little evidence to suggest that Gleason score or race modified these associations.
Conclusions: This study provides evidence that balding status assessed at a mean age
of 60 years may serve as a clinical marker for circulating sex hormone concentrations.
The weak-to-null associations between balding status and intraprostatic sex
hormones reaffirm differences in organ-specific sex hormone metabolism, implying
that other sex steroid hormone-related factors (eg, androgen receptor) play
important roles in organ-specific androgenic actions, and that other overlapping
pathways may be involved in associations between the two complex conditions.
KEYWORDS

chest hair density, male pattern baldness, prostate tissue, serum, sex steroid hormones

1 | INTRODUCTION

born with 5α-reductase type II (5αR2, which intracellularly converts
testosterone to DHT) deficiency,17 or castrated before puberty show

Androgens have long been hypothesized to underlie the development

complete retention of scalp hair.18 The former observation has led to

of prostate cancer. However, the association between serum sex

the use of finasteride (a 5αR2 inhibitor) in balding treatment, which

steroid hormones and prostate cancer risk remains inconsistent. A

slows scalp hair loss and promotes new scalp hair growth.19

meta-analysis of 18 prospective studies reported null associations
1

Although no study has assessed the direct relationship between

using study-specific circulating concentrations, albeit limited by the

chest hair density and prostate cancer risk, associations between chest

use of blood at a single time-point after midlife that may have missed

hair density and circulating sex steroid hormones have been reported.

the etiologically relevant time window, and a potentially diluted effect

The development of chest hair parallels the surge of androgens in men

through inclusion of a variable proportion of indolent prostate cancer

during puberty.20 Denser chest hair has been correlated with higher

cases in the era of prostate-specific antigen (PSA) testing. Later

levels of circulating 3α-androstanediol glucuronide (3α-diol-G; a

epidemiologic studies also did not support the association between

metabolite of DHT in peripheral tissue)21 and lower SHBG concen-

2–4

although

trations.22 Given the role of androgenic action in these dermatological

some subgroup analyses reported a positive association of aggressive

phenotypes, we investigated clinically assessed balding status and

prostate cancer with total testosterone/sex hormone-binding globulin

chest hair density in relation to circulating and intraprostatic

(SHBG) ratio,5,6 and an inverse association with the highest quintile of

concentrations of sex steroid hormones in the NCI Prostate Tissue

total estradiol/total testosterone ratio.7

Study in an attempt to understand the potential biological mechanisms

circulating sex steroid hormones and prostate cancer risk,

Despite the paucity of evidence for an association between
circulating sex steroid hormones and prostate cancer risk, androgenic

underlying associations between the dermatological phenotypes and
prostate cancer risk.

alopecia (also commonly known as male pattern baldness) used as a
proxy for early-life or cumulative exposure to sex steroid hormones
has been reported to be associated with aggressive and fatal prostate
cancer.8–10 Male pattern baldness is the most common hair loss in men
and affects approximately 50% of Caucasian men by age 50. Bald scalp

2 | MATERIALS AND METHO DS
2.1 | Study population

overexpresses androgen receptor (AR)11–14 and has higher levels of

A detailed description of the Prostate Tissue Study has been reported

dihydrotestosterone (DHT),15 compared with the non-bald region.

elsewhere.23 In brief, 422 patients were enrolled from five hospitals

This enhanced androgenic action induces miniaturization of scalp hair

during January 2000 to April 2004. Eligible study subjects were

follicles and causes progressive hair loss.16 On the other hand, men

men aged 18 years or older, scheduled for prostatectomy or
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cystoprostatectomy, newly diagnosed with localized prostate cancer,

tissue weight. In-house assays for tissue hormones had small

and had not taken any medication that may influence sex steroid

technical variability with CVs below 20% (mean = 13.8%) for all,

hormone concentrations (eg, dehydroepiandrosterone [DHEA], finas-

except for androstenedione (21%). CVs were calculated on the

teride, and neoadjuvant hormone therapy) during the 24 h preceding

logarithmic scale using a mixed model including an average of six

surgery.

technical replicates from each of five different individuals. For

Each patient provided 30 mL of fasting blood before surgery,

intraprostatic sex steroid hormone analysis, we used all eligible

which was aliquoted within 4 h at room temperature and subsequently

pieces of adjacent normal tissue regardless of sampling locations to

frozen at −70°C. During surgery and immediately after the prostate

calculate subject-level mean concentrations, as our pilot study of 30

gland was resected, the pathologist sliced a maximum of three pieces

prostate cancer patients showed that this provided generally

of macroscopically normal tissue from each of the peripheral and non-

superior CV and intra-class correlation coefficient (ICC) values,

peripheral zones of the prostate, each piece weighing 200-400 mg.

compared with using the mean concentrations of solely peripheral or

Each macroscopically normal tissue had the ends trimmed and fixed in

solely non-peripheral tissue.23 Both serum and tissue sex steroids

formalin for Haemotoxylin and Eosin stain. A genitourinary pathologist

RIAs used tritiated internal standards, and the concentrations were

(I.A.S.) subsequently evaluated the morphology and histology of these

corrected for procedural losses ranging from 15% to 30%.

margins to rule out slices containing cancer. The remaining tissue was
placed in a pre-labeled cryovial, flash frozen in liquid nitrogen and
stored at −70°C.

2.3 | Exposure measurement

Each patient underwent a physical examination before surgery by

Trained hospital nurses assessed scalp hair pattern using a Norwood-

trained hospital nurses for anthropometric and dermatological

Hamilton Scale26 and grouped participants into three categories: 1)

information and a follow-up telephone interview approximately six

no/little baldness (I/II); 2) vertex baldness (III-vertex, IV/V/Va/VI,

weeks after surgery for information on demographics, medical history,

and VII); and 3) frontal baldness (IIa/III/IIIa/IVa) (Supplementary

family history of cancer, and lifestyle. Medical and pathology reports

Figure S1). A previous validation study asked dermatologists and

were also extracted.

residents to rate balding patterns using Norwood-Hamilton scale
against photographs of male heads, reporting modest ICCs (0.63-

2.2 | Sex steroid hormone quantitation

0.68) for original classes and recommending reduced classes to
achieve higher ICCs.27 Therefore, the three-level balding variable

Sex steroid hormones were quantified at the University of Southern

was further collapsed into two categories: no/little versus any

California under the direction of F.Z.S. A detailed description of sample

baldness to minimize potential misclassification. Chest hair density

handling and laboratory process have been previously reported.23 In

was originally measured on the Ferriman-Gallwey five-level scale (ie,

brief, serum concentrations of total testosterone (testosterone), DHT,

none, sparse, moderate, dense, and very dense).28 A previous

4-Androstene-3, 17-dione (androstenedione), estrone, and total

validation

estradiol (estradiol) were measured by in-house radioimmunoassays

(kappa = 0.80) for the original scale among Turkish women.29 This

(RIA), 3α-diol-G was measured by a commercial RIA kit (Diagnostics

variable was subsequently collapsed into three categories in the

Systems Laboratories, Webster TX, presently Beckman-Coulter,

analysis: none-to-sparse (lowest two levels), moderate, and dense

Minneapolis, MD), and SHBG was measured by a solid-phase, two-

(highest two levels).

study

reported

good

inter-observer

agreement

site chemiluminescent immunometric assay on the Immulite analyzer
(Diagnostic Products Corporation, Los Angeles, CA, presently Siemens
Healthcare Diagnostics, Deerfield, IL) during 2007. RIAs were used

2.4 | Analytic sample

after organic solvent extraction to remove conjugated steroids and

Of 422 enrolled patients, we included 248 prostate cancer patients

Celite column partition chromatography to separate potential

for this analysis, after excluding 148 without sex hormones assayed

interfering unconjugated steroids. In addition, highly specific antisera

in tissue, 14 without a diagnosis of prostate cancer, one without

were used in the RIAs to provide added specificity. Concentrations of

serum hormones and 11 without any measured dermatological

serum free testosterone and free estradiol were calculated using

information.

validated algorithms.24,25 Coefficients of variation (CV)—calculated on
the logarithmic scale using a mixed model which included 2-7
replicates from each of seven different individuals—were all less
than 15% (mean = 10%).

2.5 | Statistical analysis
Pearson χ2 tests assessed independence of categorical patient

Intraprostatic sex steroid hormones, including androstenedione,

characteristics from balding status and chest hair density. Partial

testosterone, DHT, 3α-diol-G, estrone, and estradiol, were extracted

Spearmen's correlation coefficients were estimated for pairs of

from each homogenized prostate tissue sample weighing 100-

circulating and intraprostatic sex hormones, adjusting for continuous

400 mg during 2008-2009. These hormones then underwent the

age at surgery and body mass index (BMI, kg/m2). General linear

same preparation procedures and RIAs as in the serum hormone

models estimated geometric means and 95% confidence intervals

quantitation, and were expressed as picograms per gram of wet

(95%CIs) of hormones by balding status, chest hair density and Gleason
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ZHOU

|

ET AL.

score (from prostatectomy or biopsy) with adjustment for pre-defined

testosterone, DHT, and SHBG in serum, and estrone, estradiol, and

potential confounding variables including age at surgery, study site,

androstenedione/estrone ratio in tissue (Supplemental Table S3).

race, BMI, education, smoking status, and regular alcohol use. As

However, associations were in the same direction among African

hormone variables were skewed, natural log transformation was

Americans, and multiplicative interactions were null between balding

applied to non-missing values, and patients with missing values were

status and race for individual hormone variables. Given androgenic

dropped from regression models for individual hormone variables.

sensitivity differs by scalp region,15 we also presented geometric

Missing values of potential confounding variables were included in

means by three-level scalp balding category in Supplemental

regression models as a separate category. Subgroup analyses were

Table S4, despite limited counts for frontal balding only (n = 20).

performed by Gleason score (<7 vs ≥7) and race (European American vs

Distributions of hormone variables were similar between frontal

African American).

balding only and vertex plus frontal balding, although the latter

We also conducted two sensitivity analyses: 1) for intraprostatic
sex steroid hormones, we used the mean concentrations of two

group appeared to have higher androstenedione in serum
(P = 0.013).

randomly selected tissue pieces to evaluate the robustness of the main

Sensitivity analyses in which tertiles of each hormone variable

results in general linear models, given the potential variation in

were modeled as the exposure, as opposed to the outcome, provided

measurement errors from the use of a variable number of eligible tissue

mostly consistent results, except that the association for intraprostatic

pieces per subject (median = 4); and 2) we alternatively modeled

testosterone concentrations became null and an inverse association

balding status or three-level chest hair density as the outcome and

for intraprostatic androstenedione/estrone ratio was observed

tertiles of each hormone variable as the exposure using binary and

(adjusted Ptrend = 0.042, Supplemental Table S5). Increased SHBG

ordinal logistic regression, respectively. To assess trends across

appeared to drive the association for testosterone in serum; when we

tertiles, we assigned the median value of each tertile and modeled

modeled testosterone and SHBG simultaneously, the positive

this as a continuous variable in logistic regressions.

association for testosterone was attenuated to the null (ORthird

Two-sided P values <0.05 were considered statistically significant.
SAS v9.3 (SAS Institute, Inc., Cary, NC) was used for statistical analyses.

vs first tertile

tertile

= 1.62, 95%CI = 0.67-3.91), whereas the positive associa-

tion for SHBG remained significant (ORthird tertile vs first tertile = 3.00, 95%
CI = 1.19-7.53) (data not tabulated). Results were consistent when we
simultaneously modeled testosterone and SHBG as continuous

3 | RE SULTS

variables (Ptestosterone = 0.83 and PSHBG = 0.01). Tentative evidence
was found that increased testosterone drove the association for

Of the 248 patients in this analysis, 144 (58%) presented some degree of

estradiol in serum, as simultaneous adjustment for continuous

baldness and 52 (22%) some degree of dense chest hair (Table 1). Age-

testosterone and estradiol attenuated the association for estradiol

adjusted correlation between binary balding status and three-level chest

to the null (Pestradiol = 0.197 and Ptestosterone = 0.05), but simultaneous

hair density was weak (r = 0.05). Patient characteristics distributed evenly

adjustment for tertiles of these hormones attenuated the associations

by balding status, while patients with dense chest hair were more likely to

to the null for both estradiol (ORthird

be European Americans, have a college degree or higher, and have high-

CI = 0.90-5.20) and testosterone (ORthird tertile vs first tertile = 2.03, 95%

grade prostate cancer. After adjustment for age, differences in these

CI = 0.90-4.57) (data not tabulated).

tertile vs first tertile

= 2.16, 95%

characteristics by chest hair density became minimal (data not tabulated).

Geometric means of hormone variables by chest hair density

Supplemental Table S1 shows the distribution of crude concentrations of

provided no evidence of an association (Table 3). There was little

sex hormones and SHBG. Partial Spearmen's correlation coefficients

evidence for effect modification by Gleason score (Supplemental

adjusted for age and BMI demonstrated very strong correlations for pairs

Table S6) or race (Supplemental Table S7). Compared with the main

of testosterone and DHT (r = 0.74), testosterone and SHBG (r = 0.68),

results for chest hair density, modeling tertiles of each hormone

testosterone and estradiol (r = 0.53), DHT and SHBG (r = 0.61), and

variables as the exposure resulted in similarly null associations

estrone and estradiol (r = 0.66) in serum, as well as estrone and estradiol

(Supplemental Table S5).

(r = 0.64) in tissue (data not tabulated).

Sensitivity analyses for intraprostatic sex steroid hormones that

Geometric means of hormone variables by balding status are

used two pieces of randomly selected adjacent normal tissue per

shown in Table 2. Bald patients were more likely to have higher

subject did not materially alter the results, compared with the main

serum testosterone, DHT, estrone, estradiol, and SHBG, as well as

models that used all eligible tissues (data not tabulated).

higher intraprostatic testosterone concentrations with full adjustment for potential confounding variables. Stratified analyses by
Gleason score showed that such associations were mainly observed

4 | DISCUSSION

in Gleason score ≥7 prostate cancers, although the multiplicative
interaction between balding status and Gleason score for each

In this study, serum and intraprostatic sex steroid hormones were

hormone variable was not statistically significant (Supplemental

quantified in relation to male pattern baldness and chest hair density in

Table S2). Meanwhile, stratified analyses by race demonstrated that

men diagnosed with localized prostate cancer. We found evidence for

only bald European Americans had statistically significantly higher

strong positive associations of circulating testosterone, DHT, estradiol,
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Patient characteristics by balding status and chest hair density (N = 248)
Chest hair density (n = 239)a

Balding status (n = 248)
Characteristics

No (n = 104)

Any (n = 144)

N

104

143

Mean (SD)

58.4 (8.1)

60.4 (6.4)

P-valueb

None/sparse (n = 110)

109

77

52

0.055c

60.0 (7.3)

59.4 (7.6)

59.0 (6.4)

0.803c

27 (24.5%)

23 (29.9%)

16 (30.8%)

0.945d

Moderate (n = 77)

Dense (n = 52)

P-valueb

Age at surgery (years)

≤55

37 (35.6%)

32 (22.2%)

56-60

23 (22.1%)

44 (30.6%)

32 (29.1%)

20 (26.0%)

14 (26.9%)

61-65

25 (24.0%)

32 (22.2%)

26 (23.6%)

16 (20.8%)

13 (25.0%)

>65

19 (18.3%)

35 (24.3%)

24 (21.8%)

18 (23.4%)

9 (17.3%)

Race
European American

0.088

d

0.291
61 (58.7%)

<0.001

73 (50.7%)

40 (36.4%)

50 (64.9%)

36 (69.2%)

African American

38 (36.5%)

68 (47.2%)

66 (60.0%)

26 (33.8%)

13 (25.0%)

Other

3 (2.9%)

3 (2.1%)

4 (3.6%)

1 (1.3%)

1 (1.9%)

Less than high school

8 (7.7%)

12 (8.3%)

16 (14.5%)

3 (3.9%)

0 (0%)

High school/Technical school

25 (24.0%)

33 (22.9%)

26 (23.6%)

23 (29.9%)

9 (17.3%)

College or higher

58 (55.8%)

73 (50.7%)

50 (45.5%)

35 (45.5%)

38 (73.1%)

Education

0.935

Gleason score

<0.001

0.822

0.009

<7

56 (53.8%)

81 (56.3%)

57 (51.8%)

53 (68.8%)

20 (38.5%)

=7

38 (36.5%)

55 (38.2%)

42 (38.2%)

23 (29.9%)

28 (53.8%)

>7

6 (5.8%)

6 (4.2%)

6 (5.5%)

1 (1.3%)

4 (7.7%)

102

143

109

77

51

26.7 (3.9)

29.1 (13.7)

27.3 (2.9)

0.139c

36 (32.7%)

18 (23.4%)

11 (21.2%)

0.115d

57 (51.8%)

38 (49.4%)

33 (63.5%)

17 (15.5%)

21 (27.3%)

8 (15.4%)

Body mass index (BMI, kg/m2)
N

c

Mean (SD)

26.9 (3.3)

28.1 (10.4)

0.358

<25.0

29 (27.9%)

37 (25.7%)

0.593d

25.0-29.9

58 (55.8%)

76 (52.8%)

≥30.0

17 (16.3%)

31 (21.5%)

Smoking status

0.295

0.162

Never

38 (36.5%)

48 (33.3%)

36 (32.7%)

25 (32.5%)

23 (44.2%)

Former

38 (36.5%)

55 (38.2%)

39 (35.5%)

32 (41.6%)

16 (30.8%)

Current

12 (11.5%)

8 (5.6%)

12 (10.9%)

2 (2.6%)

5 (9.6%)

Never

31 (29.8%)

45 (31.3%)

35 (31.8%)

23 (29.9%)

14 (26.9%)

Former

11 (10.6%)

25 (17.4%)

19 (17.3%)

9 (11.7%)

5 (9.6%)

Current

49 (47.1%)

47 (32.6%)

38 (34.5%)

29 (37.7%)

27 (51.9%)

Regular alcohol use

0.087

0.347

Column percentage does not add up to 100% due to missing data.
a
Nine prostate cancer patients were excluded for tabulation of chest hair density due to missing data.
b
P-values were computed by Wilcoxon Rank-sum test for continuous variables and Chi-square/Fisher's exact test for categorical variables using non-missing
values.
c
P-values were calculated for the continuous covariate.
d
P-values were calculated for the categorical covariate.

and SHBG with male pattern baldness. However, we found limited

Gleason score or race modified these relationships, although the

evidence for associations between intraprostatic sex hormones and

statistical power for interaction tests may be limited by the modest

baldness, although the direction of these associations was consistent

sample size.

with what was observed in the serum analyses. Neither circulating nor

Both the prostate gland and human hair follicles are responsive to

intraprostatic sex hormones were statistically significantly associated

sex steroid hormones. Testosterone produced by Leydig cells of the

with chest hair density. There was little evidence to suggest that

testes is the predominant circulating androgen in men and is
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Geometric means of sex steroid hormones and SHBG by balding status at mean age of 60 years (N = 248)
Minimally adjusteda

Fully adjustedb

N

No (n = 104)

Any (n = 144)

P-valuec

No (n = 104)

Any (n = 144)

P-valuec

T

248

420.1 (387.9, 455.0)

481.5 (450.1, 515.1)

0.012

416.4 (384.1, 451.3)

484.6 (452.8, 518.6)

0.006

DHT

248

46.4 (43.0, 50.0)

53.7 (50.4, 57.2)

0.004

45.9 (42.7, 49.4)

54.1 (50.9, 57.5)

0.001

Sex hormones
Serum (ng/dl)

3α-diol-G

248

507.2 (458.3, 561.2)

492.3 (451.9, 536.3)

0.663

500.3 (451.4, 554.4)

497.2 (456.0, 542.1)

0.930

A

248

67.9 (62.7, 73.4)

70.1 (65.6, 75.0)

0.539

66.9 (61.7, 72.5)

70.9 (66.2, 75.9)

0.294

E1

248

5.0 (4.7, 5.4)

5.6 (5.3, 5.9)

0.030

5.0 (4.7, 5.4)

5.6 (5.3, 5.9)

0.027

E2

248

2.9 (2.7, 3.1)

3.3 (3.1, 3.5)

0.004

2.9 (2.7, 3.1)

3.2 (3.1, 3.4)

0.010

T/E2 ratio

248

147.7 (135.8, 160.6)

147.1 (137.0, 157.9)

0.948

144.9 (134.0, 156.7)

149.1 (139.6, 159.3)

0.592

A/E1 ratio

248

13.5 (12.4, 14.6)

12.6 (11.8, 13.6)

0.242

13.3 (12.3, 14.4)

12.8 (11.9, 13.7)

0.458

SHBG (nmol/L)

248

29.8 (27.7, 32.0)

35.4 (33.3, 37.6)

0.001

29.7 (27.7, 31.9)

35.4 (33.4, 37.6)

<0.001

Free T

248

10.7 (9.9, 11.4)

11.4 (10.8, 12.1)

0.140

10.6 (9.8, 11.4)

11.5 (10.8, 12.2)

0.092

Free E2

248

0.08 (0.08, 0.09)

0.09 (0.08, 0.09)

0.064

0.08 (0.08, 0.09)

0.09 (0.08, 0.09)

0.138

Adjacent normal prostate tissue (pg/g W)
T

245

205.1 (187.7, 224.1)

230.5 (214.1, 248.0)

0.051

204.3 (186.8, 223.4)

230.9 (214.4, 248.6)

0.045

DHT

248

6433.6 (6080.3, 6807.4)

6663.9 (6353.2, 6989.8)

0.357

6456.1 (6104.7, 6827.7)

6647.1 (6341.3, 6967.7)

0.446

3α-diol-G

244

2599.8 (2402.7, 2813.1)

2704.4 (2527.2, 2894.1)

0.463

2568.4 (2372.7, 2780.2)

2731.1 (2552.3, 2922.5)

0.261

A

229

593.3 (537.8, 654.5)

579.4 (534.1, 628.6)

0.719

585.1 (529.9, 646.1)

581.5 (535.9, 630.8)

0.924

E1

232

67.0 (61.2, 73.2)

75.6 (70.2, 81.4)

0.044

67.5 (61.8, 73.6)

75.2 (70.0, 80.8)

0.065

E2

232

44.2 (40.1, 48.8)

51.3 (47.3, 55.7)

0.024

44.8 (40.6, 49.4)

50.7 (46.7, 55.0)

0.062

T/E2 ratio

232

4.6 (4.2, 5.0)

4.4 (4.0, 4.7)

0.500

4.5 (4.1, 4.9)

4.4 (4.1, 4.8)

0.831

A/E1 ratio

220

9.0 (8.0, 10.1)

7.7 (7.0, 8.5)

0.050

8.9 (7.9, 9.9)

7.8 (7.1, 8.5)

0.086

A, androstenedione; DHT, dihydrotestosterone; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin; T, testosterone; 3α-diol-G,
3α-androstanediol glucuronide.
a
Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (five sites, not listed here).
b
Additionally adjusted for BMI (<25.0, 25.0-29.9, ≥30.0 kg/m2), education (less than high school, high school/technical school, college or higher, unknown),
smoking status (never, former, current, unknown), and regular alcohol use (never, former, current, unknown).
c
P-values were calculated for a global test of differences in geometric means.

irreversibly converted to the most potent androgen, DHT, by 5αR in

the predominant form expressed in chest skin.40 However, chest hair

many peripheral tissues, such as the prostate and skin. DHT and, to a

follicles have been suggested to be less androgen-dependent,41 and

lesser extent, testosterone intracellularly bind to AR stimulating

this is in line with the null association of chest hair density with sex

downstream androgenic action including hair stimulation and inhibi-

steroid hormones in this analysis, albeit two prior observational studies

tion, as well as prostate growth and carcinogenesis. There are three

have reported otherwise.21,22

isoenzymes of 5αR (types I, II, and III). The function of 5αR3 in the

Direct comparison of results from epidemiological studies on

prostate remains unclear but previous studies reported its role in

circulating sex hormones in relation to male pattern baldness is

converting testosterone to DHT in castration resistant prostate

challenging given differences in age, race, laboratory assays (eg, RIA,

cancers.

30,31

Meanwhile, 5αR1 and 5αR2 are consistently related to

mass

spectrometry,

electrochemiluminescence

immunoassay),

testosterone metabolism, and are expressed at different body sites and

health status (with/without malignancy/other metabolic diseases),

organ compartments.32 Prostatic epithelium and stroma express

and balding categories. Several small studies (n = 6) have assessed

higher concentrations of 5αR2,33 as highlighted by an efficient

this relationship among apparently healthy younger (<45 years old)

27

and

men and found conflicting associations; some reported that bald

by its comparable efficacy to dutasteride (a dual inhibitor for 5αR1 and

men were more likely to have increased testosterone,15,42 increased

reduction in intraprostatic DHT through finasteride treatment
34

Meanwhile,

testosterone/SHBG ratio,42,43 increased DHT15 and decreased

sebaceous glands predominantly express 5αR1, and scalp hair follicles

SHBG levels,42–44 whereas others have reported either null or

5αR2) treatment for benign prostatic hyperplasia.
35–37

Both isoenzymes play critical roles

opposing findings.45,46 On the other hand, a cross-sectional study

in balding development as supported by the superior efficacy of

among older (>65 years) healthy Greek men specifically compared

dutasteride versus finasteride in treating baldness.38,39 Lastly, 5αR1 is

vertex balding to those without (ie, no/minimal plus frontal balding

produce higher levels of 5αR2.

239

239

239

SHBG, nmol/L

Free T

Free E2

0.08 (0.07, 0.09)

11.3 (10.5, 12.1)

34.9 (32.4, 37.6)

13.8 (12.7, 15.0)

160.1 (147.2, 174.2)

3.0 (2.8, 3.2)

5.0 (4.7, 5.4)

69.7 (64.3, 75.5)

470.3 (425.7, 519.5)

52.3 (48.4, 56.5)

472.8 (436.1, 512.6)

None/Sparse (n = 110)

239

236

222

223

223

223

213

DHT

3α-diol-G

A

E1

E2

T/E2 ratio

A/E1 ratio

8.9 (8.0, 10.0)

4.8 (4.4, 5.3)

45.2 (41.1, 49.7)

65.8 (60.2, 71.9)

578.0 (524.2, 637.3)

2623.5 (2425.9, 2837.3)

6769.1 (6403.8, 7155.3)

222.2 (204.0, 241.9)

7.8 (6.8, 8.9)

4.1 (3.7, 4.59)

49.2 (44.1, 54.9)

74.1 (66.8, 82.1)

574.1 (512.1, 643.6)

2621.9 (2393.2, 2872.5)

6288.2 (5896.0, 6706.5)

208.6 (189.1, 230.1)

0.09 (0.08, 0.09)

10.9 (10.1, 11.9)

32.1 (29.4, 34.9)

12.8 (11.6, 14.0)

141.8 (128.6, 156.3)

3.1 (2.9, 3.4)

5.4 (5.0, 5.9)

69.4 (63.2, 76.1)

538.4 (479.7, 604.3)

48.5 (44.3, 53.0)

443.9 (404.1, 487.6)

Moderate (n = 77)

7.9 (6.7, 9.3)

4.4 (3.9, 5.1)

49.2 (42.8, 56.6)

78.0 (68.5, 88.9)

616.2 (534.8, 710.0)

2792.0 (2491.7, 3128.5)

6492.1 (5991.6, 7034.3)

219.9 (194.1, 249.2)

0.09 (0.08, 0.10)

11.0 (9.9, 12.2)

30.3 (27.2, 33.7)

11.8 (10.5, 13.4)

130.7 (115.8, 147.7)

3.3 (3.0, 3.7)

5.8 (5.3, 6.4)

68.6 (61.0, 77.0)

518.6 (449.1, 598.8)

50.7 (45.3, 56.7)

434.3 (386.4, 488.3)

Dense (n = 52)

0.277

0.130

0.463

0.082

0.709

0.638

0.250

0.622

0.043

0.873

0.098

0.121

0.027

0.208

0.074

0.976

0.221

0.458

0.454

P-valuec

8.7 (7.7, 9.7)

4.6 (4.2, 5.1)

46.2 (41.9, 50.9)

68.2 (62.5, 74.5)

582.4 (527.0, 643.7)

2681.3 (2476.6, 2902.8)

6769.9 (6404.7, 7156.0)

219.7 (201.3, 239.7)

0.08 (0.08, 0.09)

11.2 (10.4, 12.1)

34.1 (31.7, 36.7)

13.5 (12.4, 14.7)

152.9 (141.3, 165.5)

3.0 (2.8, 3.3)

5.2 (4.8, 5.5)

69.6 (64.0, 75.7)

474.7 (429.0, 525.4)

51.1 (47.3, 55.1)

466.3 (429.4, 506.3)

None/Sparse (n = 110)

Fully adjustedb

7.9 (6.9, 9.0)

4.2 (3.7, 4.7)

48.8 (43.7, 54.6)

71.7 (64.7, 79.5)

564.8 (502.2, 635.3)

2591.4 (2362.0, 2843.1)

6326.7 (5930.2, 6749.7)

211.6 (191.2, 234.1)

0.08 (0.08, 0.09)

11.2 (10.3, 12.2)

32.6 (29.9, 35.5)

13.1 (11.9, 14.4)

150.5 (137.2, 165.0)

3.0 (2.8, 3.3)

5.3 (4.9, 5.7)

69.6 (63.1, 76.7)

535.6 (475.8, 602.8)

50.5 (46.2, 55.1)

456.4 (414.5, 502.4)

Moderate (n = 77)

8.1 (6.9, 9.6)

4.6 (4.0, 5.3)

47.3 (41.0, 54.5)

76.0 (66.7, 86.5)

613.1 (530.1, 709.1)

2723.4 (2425.5, 3057.8)

6432.0 (5934.3, 6971.5)

219.9 (193.4, 250.1)

0.09 (0.08, 0.10)

10.7 (9.6, 11.9)

31.1 (27.9, 34.6)

11.9 (10.6, 13.5)

131.9 (117.5, 147.9)

3.3 (2.9, 3.6)

5.7 (5.2, 6.3)

68.4 (60.6, 77.2)

512.3 (442.2, 593.5)

50.3 (45.1, 56.1)

429.3 (380.9, 483.9)

Dense (n = 52)

0.606

0.378

0.772

0.428

0.685

0.775

0.303

0.839

0.306

0.772

0.405

0.282

0.111

0.536

0.248

0.968

0.338

0.971

0.558

P-valuec

A, androstenedione; DHT, dihydrotestosterone; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin; T, testosterone; 3α-diol-G, 3α-androstanediol glucuronide.
a
Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here).
b
Additionally adjusted for BMI (<25.0, 25.0-29.9, ≥30.0 kg/m2), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown), and
regular alcohol use (never, former, current, unknown).
c
P-values were calculated for a global test of differences in geometric means.

236

T

Adjacent normal prostate tissue (pg/g W)

239

A/E1 ratio

239

E1

239

239

A

239

239

3α-diol-G

T/E2 ratio

239

DHT

E2

239

T

Serum (ng/dL)

N

Minimally adjusteda

Geometric means of sex steroid hormones and SHBG by chest hair density at mean age of 60 years (N = 239)

Sex hormones
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only) and did not find associations for serum testosterone, estradiol,
22

ET AL.

could not be assessed. Meanwhile, male pattern baldness at older

Furthermore, another study in the US among

age may reflect cumulative exposure to circulating sex steroid

268 prostate cancer cases and controls found that men with vertex

hormones as opposed to the single time-point we have assessed in

balding had higher serum age- and race-adjusted free testosterone

serum and tissue at the age of prostate cancer diagnosis

levels than those who had little or no hair loss.47

(mean = 60, range = 37-86 years), and this mismatched time-

DHEA-S, or SHBG.

This study supports associations of circulating sex hormones

window of sex hormone exposure may have reduced statistical

with male pattern baldness in an older prostate cancer population.

power. Second, we combined hair-loss patterns because the

However, comparisons between our results with previously pub-

number of frontal balding only was relatively small. Although we

lished studies requires caution. First, there is evidence that the

were unable to specify whether observed associations were

presence of prostate cancer may slightly suppress circulating

modified by hair-loss patterns, the misclassification of balding

testosterone concentrations through the hypothalamic-pituitary

status was minimized.

axis.48–51 Thus, associations observed in this case series may differ

In conclusion, this study provides evidence that elevated

from what may be expected in a healthy population. Second, our

circulating testosterone, DHT, estradiol, and SHBG are associated

analytical sample is older, compared to most prior studies, with a

with balding status in prostate cancer cases. Male balding serves as a

mean age of 60 years. It is known that circulating testosterone

proxy for circulating sex hormone concentrations and may explain

decreases,52–54 while male pattern baldness progresses with

prior studies showing an association between male pattern baldness

advancing age.55 However, we would expect minimal confounding

and prostate cancer incidence and specific mortality. Testosterone is

by age in this study because distributions of age were not

the only elevated intraprostatic sex hormone in men with balding; lack

statistically significantly different by balding status and we adjusted

of an association between balding and other intraprostatic sex

for age in regression models.

hormones reaffirms differences in organ-specific sex steroid hormone

Given the strong parallels in androgen dependency and in age-

metabolism and cellular response.

related changes between scalp hair follicles and the prostate, we
speculated that male pattern baldness might serve as a proxy for
intrinsic enhanced androgenic action in androgen-responsive organs.
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DHT, and estradiol in normal tissue adjacent to Gleason ≥7 tumor
foci versus Gleason <7 foci (Supplemental Table S1)—we did not find
evidence that Gleason score modified the association between
intraprostatic sex hormones and balding status (Supplemental
Table S3).
Strengths of this study include central review by an experienced genitourinary pathologist, nurse-assessed dermatological
characteristics, and simultaneous measurement of circulating and
intraprostatic sex steroid hormones. Limitations include the fact
that both circulating and intraprostatic sex hormones were only
measured once and, therefore, intra-individual temporal variations
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Supplemental Fig 1. Modified Norwood-Hamilton Seal. usN! to sco~ hair loss patlerns in NCI
Study

Prostat~ 'Jis5U~

No baldn.,."

{J ~ ~ {J ~ ~

eeeee

m_

VeriH + Frontal

V

~

~

~

baldn ~,

{J ~ ~ ~
~

e

Frontal haldness

m

~

e-

~

~

No

~
""
~-

